Blood test could spot cervical cancer return earlier
NCT ID NCT04574635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test can find DNA from the HPV virus that causes cervical cancer. Researchers will collect blood samples from 18 people with cervical cancer before, during, and after treatment. The goal is to see if the test can predict how well treatment works and detect if the cancer comes back sooner than standard methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to monitor cervical cancer and catch recurrences earlier.
- What could go wrong
- This is a very small, early-stage study with only 18 participants, so results may not apply to all patients. The test may not be sensitive enough to detect all cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOSQUAMOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Intermittent fasting tested to ease radiation side effects in cancer patients
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Custom-Made cancer vaccine shows promise in advanced tumors
- New smart chemo targets tumors, spares healthy tissue
- Experimental drug plus radiation shows promise for recurrent gynecologic cancers